Aktuellt
SENASTE
Tumorad-01 has entered the clinical stage, a significant milestone for Spago Nanomedical’s lead radiopharmaceutical oncology program Tumorad. Spago’s study is initiated in Australia, which is positive in our view, and, given the short time from approval to FPI, suggests no issues with finding patients. We expect Spago to add patients and centres from now on, and we expect early safety and biodistribution data from a handful of patients in this open phase 1 (evolving to phase 2a in the next stage) study before mid-2024. We also expect full results from late 2024 to early 2025, with possibility to include early signs of efficacy.
LÄS MER
